الفهرس 
Trabeculectomy
RISK FACTORS FOR FAILURE OF TRABECULECTOMYOnly 14 pages are availabe for public view
 |  | from | 130 |  |  |
| | | from | 130 | | |
Abstract
This study aimed at exploring the hypothesis that the Ologen
implant and the bevacizumab may be safe and effective alternatives to the
use of MMC for trabeculectomy procedures. from our results; we
confirm the effectiveness of MMC in controlling scar formation after
trabeculectomy, but it was associated with some side effects. We
conclude that the Ologen implant may be a safe and effective alternative
to MMC in terms of IOP reduction, and it may avoid the side effects
associated with the use of MMC. With 1.25mg subconjunctival
bevacizumab in trabeculectomy, we cannot reach a conclusion that it can
be a MMC substitute in augmented trabeculectomy, as it had a lower
success rate and was associated with some complications.
Recommendations
A larger randomized trials and a longer follow-up period are
warranted to determine the possible long-term complications of
subconjunctival bevacizumab and Ologen and their effects on the
outcome of trabeculectomy.
The dose and frequency of subconjunctival injection of anti-VEGF
may need more investigational studies to reach its optimal effect as
an anti-scarring agent after trabeculectomy.